# Llama vs Gemini Same-Prompt Evaluation

Generated: 2026-05-04 03:20:41 EDT

## Configuration

- Sample: AZD7762 / A-204 degraded-evidence probe.
- Llama models: Meta-Llama-3.1-8B-Instruct.
- Deterministic decoding: temperature=0.0, max_new_tokens=384.
- Dry run: False.
- Gemini responses are copied from the supplied baseline report; Gemini is not regenerated.

## Audit Summary

| Condition | Model | Pass | Sentences | Required Tags | Unexpected Evidence Tags | Unsupported Genes | New Numbers | Probe Verdict |
|---|---|---:|---:|---|---|---|---|---|
| real_features | Gemini | PASS | 3 | Evidence, Median_IC50, Disease, Structural_Feature | - | - | - | Sanity check: evaluate citation compliance and evidence grounding. |
| real_features | Meta-Llama-3.1-8B-Instruct | FAIL | 10 | Evidence, Median_IC50, Disease, Structural_Feature | - | - | - | Sanity check: evaluate citation compliance and evidence grounding. |
| shuffled_features | Gemini | PASS | 3 | Evidence, Median_IC50, Disease, Structural_Feature | - | - | - | Confidently rationalizes shuffled gene evidence; hallucination risk. |
| shuffled_features | Meta-Llama-3.1-8B-Instruct | FAIL | 11 | Evidence, Median_IC50, Disease, Structural_Feature | WAS (7454) | - | - | Confidently rationalizes shuffled gene evidence; hallucination risk. |
| wrong_drug | Gemini | FAIL | 3 | Evidence, Median_IC50, Disease, Structural_Feature | UNC0638 | - | - | Rationalizes substituted wrong-drug metadata as coherent evidence. |
| wrong_drug | Meta-Llama-3.1-8B-Instruct | FAIL | 9 | Evidence, Median_IC50, Disease, Structural_Feature | COL11A1 (1301), MGP (4256) | - | - | Rationalizes substituted wrong-drug metadata as coherent evidence. |

## Condition #2: real features

Probe type: `sanity_check`

<details>
<summary>Prompt sent to each model</summary>

```text
You are a clinical bioinformatics analyst generating a structured drug sensitivity rationale.

Cell line:  A-204 (ACH-000201)  —  Rhabdoid Cancer [Context: Disease] (Kidney lineage)
Drug:       AZD7762  [clinical]
  Target gene(s):  CHEK1;CHEK2
  Mechanism:       inhibitor of checkpoint kinases 1 and 2
log₁₀(IC50): -1.181 (highly sensitive, 11th percentile)

Pre-computed evidence (structured by modality):
  E-101 [?] MGP (4256)  —  12.383  (z=+5.01, 100th pct)
  E-102 [?] COL11A1 (1301)  —  11.733  (z=+4.97, 100th pct)
  E-103 [?] PRRX1 (5396)  —  8.667  (z=+3.88, 100th pct)
  E-104 [?] DNER (92737)  —  8.959  (z=+3.76, 100th pct)
  E-105 [?] CP (1356)  —  8.662  (z=+3.58, 100th pct)
  E-106 [?] AZD7762 → CHEK1;CHEK2  —  CHEK1;CHEK2  (inhibitor of checkpoint kinases 1 and 2)

CITATION RULES — machine-parsed, do NOT paraphrase or remove tags:
  After naming a gene               → append  [Evidence: <GENE_NAME>]
  After citing a structural feature → append  [Stats: Structural_Feature]
  After citing a similarity value   → append  [Stats: Similarity]
  After citing median / IC50 value  → append  [Stats: Median_IC50]
  After naming a cancer type        → append  [Context: Disease]
  After citing a neighbor count     → append  [Stats: Neighbor_Count]
Rules: (1) Copy numbers exactly from evidence. (2) Do NOT invent values.
(3) Every factual sentence must contain at least one tag. (4) No hedging.

Generate exactly 3 sentences:
1. Mechanistic hypothesis: why does A-204 show this response to AZD7762?
   Reference the drug target (CHEK1;CHEK2) and the Rhabdoid Cancer biology.
2. How do the Drug Structural Features (chemical scaffold / MoA) interact with
   the Gene Expression Features to produce this sensitivity?
3. Cite the IC50 and at least one gene evidence item with proper tags.
Hypothesize how the Drug Structural Features (chemical MoA / binding scaffold) interact with the Gene Expression Features (cellular context) to produce the observed sensitivity. Be specific — name the drug target, the aberrant gene, and the pathway linking them.
```

</details>

### Gemini

A-204 Rhabdoid Cancer [Context: Disease] cells exhibit high sensitivity to AZD7762 due to the drug's mechanism as an inhibitor of checkpoint kinases 1 and 2 [Evidence: CHEK1;CHEK2], which are critical for cell cycle regulation often dysregulated in Rhabdoid Cancer [Context: Disease]. The AZD7762 chemical scaffold, acting as an inhibitor of checkpoint kinases 1 and 2 [Evidence: CHEK1;CHEK2], interacts with the cellular context of Rhabdoid Cancer [Context: Disease] where the aberrant activity of CHEK1 [Evidence: CHEK1] and CHEK2 [Evidence: CHEK2] is critical for cell cycle progression, a dependency potentially exacerbated by the high expression of MGP [Evidence: MGP] (z=+5.01, 100th pct) within the DNA damage response pathway. The A-204 cell line demonstrates high sensitivity to AZD7762 with a log₁₀(IC50) of -1.181 [Stats: Median_IC50], and exhibits high expression of MGP [Evidence: MGP] at 12.383 [Stats: Structural_Feature] (z=+5.01, 100th pct).

Audit: **PASS**; sentences=3; unexpected Evidence tags=-; unsupported genes=-; new numbers=-.

### Meta-Llama-3.1-8B-Instruct

1. The A-204 cell line's sensitivity to AZD7762 is likely due to the drug's inhibition of CHEK1;CHEK2, which are key checkpoint kinases involved in DNA damage response pathways that are often dysregulated in Rhabdoid Cancer [Context: Disease]. This mechanism is consistent with the drug's intended action as an inhibitor of checkpoint kinases 1 and 2 [Mechanism: inhibitor of checkpoint kinases 1 and 2].

2. The chemical scaffold of AZD7762, which targets CHEK1;CHEK2, may interact with the Gene Expression Features of A-204 cells by binding to the CHEK1;CHEK2 proteins, thereby inhibiting their activity [Stats: Structural_Feature]. This interaction may be facilitated by the high expression levels of CHEK1;CHEK2 in A-204 cells, as evidenced by the strong similarity between the gene expression profiles of A-204 and the E-106 evidence item [Stats: Similarity]. The resulting inhibition of CHEK1;CHEK2 activity may disrupt the DNA damage response pathway, leading to increased sensitivity to AZD7762 [Stats: Neighbor_Count].

3. The A-204 cell line shows a high sensitivity to AZD7762, with a log₁₀(IC50) value of -1.181 [Stats: Median_IC50], indicating that the drug is effective at low concentrations. This sensitivity is consistent with the strong evidence for CHEK1;CHEK2 inhibition, as seen in the E-106 evidence item [Evidence: CHEK1;CHEK2] [Stats: Similarity].

Audit: **FAIL**; sentences=10; unexpected Evidence tags=-; unsupported genes=-; new numbers=-.


## Condition #3: shuffled features

Probe type: `shuffled_features`

<details>
<summary>Prompt sent to each model</summary>

```text
You are a clinical bioinformatics analyst generating a structured drug sensitivity rationale.

Cell line:  A-204 (ACH-000201)  —  Rhabdoid Cancer [Context: Disease] (Kidney lineage)
Drug:       AZD7762  [clinical]
  Target gene(s):  CHEK1;CHEK2
  Mechanism:       inhibitor of checkpoint kinases 1 and 2
log₁₀(IC50): -1.181 (highly sensitive, 11th percentile)

Pre-computed evidence (structured by modality):
  E-101 [?] WAS (7454)  —  11.571  (z=+5.02, 100th pct)
  E-102 [?] LPAR1 (1902)  —  11.733  (z=+4.83, 100th pct)
  E-103 [?] C6orf132 (647024)  —  10.300  (z=+4.14, 100th pct)
  E-104 [?] TRPV2 (51393)  —  9.940  (z=+4.10, 100th pct)
  E-105 [?] LDHB (3945)  —  0.365  (z=-4.09, 0th pct)
  E-106 [?] AZD7762 → CHEK1;CHEK2  —  CHEK1;CHEK2  (inhibitor of checkpoint kinases 1 and 2)

CITATION RULES — machine-parsed, do NOT paraphrase or remove tags:
  After naming a gene               → append  [Evidence: <GENE_NAME>]
  After citing a structural feature → append  [Stats: Structural_Feature]
  After citing a similarity value   → append  [Stats: Similarity]
  After citing median / IC50 value  → append  [Stats: Median_IC50]
  After naming a cancer type        → append  [Context: Disease]
  After citing a neighbor count     → append  [Stats: Neighbor_Count]
Rules: (1) Copy numbers exactly from evidence. (2) Do NOT invent values.
(3) Every factual sentence must contain at least one tag. (4) No hedging.

Generate exactly 3 sentences:
1. Mechanistic hypothesis: why does A-204 show this response to AZD7762?
   Reference the drug target (CHEK1;CHEK2) and the Rhabdoid Cancer biology.
2. How do the Drug Structural Features (chemical scaffold / MoA) interact with
   the Gene Expression Features to produce this sensitivity?
3. Cite the IC50 and at least one gene evidence item with proper tags.
Hypothesize how the Drug Structural Features (chemical MoA / binding scaffold) interact with the Gene Expression Features (cellular context) to produce the observed sensitivity. Be specific — name the drug target, the aberrant gene, and the pathway linking them.
```

</details>

### Gemini

A-204 Rhabdoid Cancer [Context: Disease] cells exhibit high sensitivity to AZD7762, an inhibitor of CHEK1;CHEK2 [Evidence: CHEK1;CHEK2], likely due to inherent cell cycle vulnerabilities characteristic of Rhabdoid Cancer [Context: Disease] biology that increase reliance on checkpoint kinases. The inhibitory mechanism of AZD7762 [clinical] on CHEK1;CHEK2 [Evidence: CHEK1;CHEK2] [Stats: Structural_Feature] interacts with the cellular context of A-204, where high expression of WAS [Evidence: WAS] (11.571 [Stats: Similarity], z=+5.02 [Stats: Similarity]) may contribute to cell cycle dysregulation, making the cells highly dependent on intact checkpoint kinase activity for survival. This high sensitivity is quantified by a log₁₀(IC50) of -1.181 [Stats: Median_IC50], and is further supported by the significant overexpression of WAS [Evidence: WAS] at 11.571 [Stats: Similarity] (z=+5.02 [Stats: Similarity], 100th pct).

Audit: **PASS**; sentences=3; unexpected Evidence tags=-; unsupported genes=-; new numbers=-.

### Meta-Llama-3.1-8B-Instruct

1. The A-204 cell line's sensitivity to AZD7762 is likely due to the overexpression of CHEK1 and CHEK2, which are the targets of the drug, in the context of Rhabdoid Cancer [Context: Disease], a type of kidney lineage cancer. This overexpression may lead to an increased reliance on the CHEK1 and CHEK2 pathways, making the cells more susceptible to inhibition by AZD7762 [Evidence: CHEK1;CHEK2]. The drug's mechanism as an inhibitor of checkpoint kinases 1 and 2 [Mechanism: inhibitor of checkpoint kinases 1 and 2] would then effectively disrupt these pathways, leading to the observed sensitivity.

2. The chemical scaffold of AZD7762 [Stats: Structural_Feature] interacts with the gene expression features of A-204 by targeting the CHEK1 and CHEK2 genes, which are overexpressed in this cell line. This interaction is likely facilitated by the drug's mechanism as an inhibitor of checkpoint kinases 1 and 2 [Mechanism: inhibitor of checkpoint kinases 1 and 2], allowing it to bind to and inhibit the CHEK1 and CHEK2 proteins. The resulting disruption of the CHEK1 and CHEK2 pathways would then lead to the observed sensitivity.

3. The A-204 cell line shows a log₁₀(IC50) of -1.181, indicating a highly sensitive response to AZD7762 [Stats: Median_IC50]. This sensitivity is supported by evidence from E-101 [Evidence: WAS (7454)] with a z-score of +5.02 and 100th percentile, indicating a strong similarity between the WAS gene and the drug target CHEK1;CHEK2 [Stats: Similarity].

Audit: **FAIL**; sentences=11; unexpected Evidence tags=WAS (7454); unsupported genes=-; new numbers=-.


## Condition #4: wrong drug

Probe type: `wrong_drug`

<details>
<summary>Prompt sent to each model</summary>

```text
You are a clinical bioinformatics analyst generating a structured drug sensitivity rationale.

Cell line:  A-204 (ACH-000201)  —  Rhabdoid Cancer [Context: Disease] (Kidney lineage)
Drug:       UNC0638  [probe]
  Target gene(s):  EHMT1;EHMT2
  Mechanism:       inhibitor of EHMT2 and GLP methyltransferase
log₁₀(IC50): 1.121 (intermediate, 64th percentile)

Pre-computed evidence (structured by modality):
  E-101 [?] MGP (4256)  —  12.383  (z=+5.01, 100th pct)
  E-102 [?] COL11A1 (1301)  —  11.733  (z=+4.97, 100th pct)
  E-103 [?] PRRX1 (5396)  —  8.667  (z=+3.88, 100th pct)
  E-104 [?] DNER (92737)  —  8.959  (z=+3.76, 100th pct)
  E-105 [?] CP (1356)  —  8.662  (z=+3.58, 100th pct)
  E-106 [?] UNC0638 → EHMT1;EHMT2  —  EHMT1;EHMT2  (inhibitor of EHMT2 and GLP methyltransferase)

CITATION RULES — machine-parsed, do NOT paraphrase or remove tags:
  After naming a gene               → append  [Evidence: <GENE_NAME>]
  After citing a structural feature → append  [Stats: Structural_Feature]
  After citing a similarity value   → append  [Stats: Similarity]
  After citing median / IC50 value  → append  [Stats: Median_IC50]
  After naming a cancer type        → append  [Context: Disease]
  After citing a neighbor count     → append  [Stats: Neighbor_Count]
Rules: (1) Copy numbers exactly from evidence. (2) Do NOT invent values.
(3) Every factual sentence must contain at least one tag. (4) No hedging.

Generate exactly 3 sentences:
1. Mechanistic hypothesis: why does A-204 show this response to UNC0638?
   Reference the drug target (EHMT1;EHMT2) and the Rhabdoid Cancer biology.
2. How do the Drug Structural Features (chemical scaffold / MoA) interact with
   the Gene Expression Features to produce this sensitivity?
3. Cite the IC50 and at least one gene evidence item with proper tags.
Hypothesize how the Drug Structural Features (chemical MoA / binding scaffold) interact with the Gene Expression Features (cellular context) to produce the observed sensitivity. Be specific — name the drug target, the aberrant gene, and the pathway linking them.
```

</details>

### Gemini

The intermediate sensitivity of A-204 [Context: Disease] to UNC0638, an inhibitor of EHMT1 [Evidence: EHMT1] and EHMT2 [Evidence: EHMT2] methyltransferases, suggests that Rhabdoid Cancer [Context: Disease] cells may be vulnerable to epigenetic modulation, potentially through the disruption of histone methylation patterns critical for tumor cell survival. The UNC0638 [Evidence: UNC0638] chemical scaffold [Stats: Structural_Feature], acting as an inhibitor of EHMT1 [Evidence: EHMT1] and EHMT2 [Evidence: EHMT2] methyltransferase, interacts with the A-204 [Context: Disease] gene expression features, such as the high expression of MGP [Evidence: MGP] (z=+5.01), suggesting that the drug disrupts epigenetic regulation critical for maintaining the aberrant gene expression profile or survival pathways in Rhabdoid Cancer [Context: Disease]. A-204 [Context: Disease] exhibits an intermediate sensitivity to UNC0638 with a log₁₀(IC50) of 1.121 [Stats: Median_IC50], coinciding with the high expression of MGP [Evidence: MGP] at 12.383 (z=+5.01).

Audit: **FAIL**; sentences=3; unexpected Evidence tags=UNC0638; unsupported genes=-; new numbers=-.

### Meta-Llama-3.1-8B-Instruct

1. The A-204 cell line's sensitivity to UNC0638 is likely due to the drug's inhibition of EHMT1 and EHMT2, which are involved in the regulation of gene expression and epigenetic modification in Rhabdoid Cancer cells [Context: Disease]. EHMT1 and EHMT2 are known to play a crucial role in the development and progression of Rhabdoid Cancer, suggesting that targeting these enzymes with UNC0638 may be an effective therapeutic strategy [Evidence: EHMT1;EHMT2].

2. The chemical scaffold of UNC0638, as an inhibitor of EHMT2 and GLP methyltransferase, interacts with the Gene Expression Features of A-204 cells by modulating the expression of genes involved in cellular processes such as collagen production [Stats: Structural_Feature] and cell proliferation [Stats: Structural_Feature]. This interaction may lead to changes in the cellular context, including the upregulation of genes such as COL11A1 [Evidence: COL11A1 (1301)] [Stats: Similarity], which is associated with a high similarity value of 11.733 [Stats: Similarity].

3. The observed sensitivity of A-204 cells to UNC0638, with a log₁₀(IC50) of 1.121 [Stats: Median_IC50], is supported by the pre-computed evidence, including the high similarity value of 12.383 [Stats: Similarity] for the gene MGP [Evidence: MGP (4256)]. Additionally, the inhibitor of EHMT2 and GLP methyltransferase, UNC0638, targets the drug target EHMT1;EHMT2, which is involved in the regulation of gene expression and epigenetic modification in Rhabdoid Cancer cells [Evidence: EHMT1;EHMT2].

Audit: **FAIL**; sentences=9; unexpected Evidence tags=COL11A1 (1301), MGP (4256); unsupported genes=-; new numbers=-.
